Abstract: The present invention relates to quality assurance methods for use in amplification techniques. such as Next Generation Sequencing (NGS).

Abstract: The present invention relates, in part, to methods for the stratification, prognosis, diagnosis and stratification of a cancer, such as an ovarian cancer or a breast cancer.

Abstract: The present invention relates, in part, to methods for the stratification, prognosis, diagnosis and stratification of a cancer, such as an ovarian cancer or a breast cancer.

Abstract: The present invention relates to quality assurance methods for use in amplification techniques, such as Next Generation Sequencing (NGS).

Abstract: The present invention relates to quality assurance methods for use in amplification techniques, such as Next Generation Sequencing (NGS).

Abstract: The present invention relates, in part, to methods for the stratification, prognosis, diagnosis and stratification of a cancer, such as an ovarian cancer or a breast cancer.

Abstract: The present invention relates to quality assurance methods for use in amplification techniques, such as Next Generation Sequencing (NGS).

Abstract: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.

Abstract: We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4 or a mouse BACH genomic sequence (SEQ ID NO: 10).

Abstract: We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder.

Abstract: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.

Abstract: The present invention relates to novel functions of a known receptor. In particular, the invention relates to the use of a galanin-like receptor and/or ligands thereof in the manipulation of the pituitary hormonal axis and reproductive systems.

Abstract: We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder.

Abstract: We disclose Conrad G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 14 or SEQ ID NO: 17 and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Conrad polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16 or SEQ ID NO: 18.

Abstract: We disclose Mowgli G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 8, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Mowgli polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10.

Abstract: We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 4 or a mouse BACH genomic sequence (SEQ ID NO:10).